Research Achievements
Shinichiro Motohashi| 2012 | 2011 | 2010 | 2009 | 2008 |
| Papers| International Conferences |
Papers
Miki‚ M. T.‚ Hasegawa‚ A.‚ Iwamura‚ C.‚ Shinoda‚ K.‚ Tofukuji‚ S.‚ Watanabe‚ Y.‚ Hosokawa‚ H.‚ Motohashi‚ S.‚ Hashimoto‚ K.‚ Shirai‚ M.‚ Yamashita‚ M.‚ and Nakayama‚ T. CD69 controls the pathogenesis of allergic airway inflammation.
J. Immunol. 2009; 183 (12): 8203-8215
Kitajima‚ M.‚ Iwamura‚ C.‚ Miki‚ H. T.‚ Shinoda‚ K.‚ Endo‚ Y.‚ Watanabe‚ Y.‚ Shinnakasu‚ R.‚ Hosokawa‚ H.‚ Hashimoto‚ K.‚ Motohashi‚ S.‚ Koseki‚ H.‚ Ohara‚ O.‚ Yamashita‚ M.‚ and Nakayama‚ T. Enhanced Th2 cell differentiation and allergen-induced airway inflammation in Zfp35-deficient mice.
J. Immunol. 2009; 183 (8): 5388-5396
Alaa M‚ Suzuki M‚ Yoshino M‚ Tian L‚ Suzuki H‚ Nagato K‚ Fujiwara T‚ Wada H‚ Moriya Y‚ Hoshino H‚ Motohashi S‚ Yoshida S‚ Shibuya K‚ Hiroshima K‚ Nakatani Y‚ Abdrabou A‚ Elkholy M‚ Mahfouz T‚ Yoshino I. Prostaglandin E2 receptor 2 overexpression in squamous cell carcinoma of the lung correlates with p16INK4A methylation and an unfavorable prognosis.
Int J Oncol. 2009; 34 (3): 805-812
Kunii N‚ Horiguchi S‚ Motohashi S‚ Yamamoto H‚ Ueno N‚ Yamamoto S‚ Sakurai D‚ Taniguchi M‚ Nakayama T‚ Okamoto Y. Combination therapy of in vitro-expanded natural killer T cells and ¦Á-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma.
Cancer Sci. 2009; 100 (6): 1092-1098
Motohashi S‚ Nagato K‚ Kunii N‚ Yamamoto H‚ Yamasaki K‚ Okita K‚ Hanaoka H‚ Shimizu N‚ Suzuki M‚ Yoshino I‚ Taniguchi M‚ Fujisawa T‚ Nakayama T. A phase I-II study of ¦Á-Galactosylceramide(KRN7000)-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer.
J. Immunol. 2009; 182 (4): 2492-2501
International Conferences
Yoshino M‚ Suzuki M‚ Moriya Y‚ Hoshino H‚ Motoahashi S‚ Yoshida S‚ Shibuya K‚ Yoshino I. Promoter hypermethylation of p16 and Wif-1 genes as an independent prognostic marker in stage IA non-small cell lung cancers
13th World Conference on Lung Cancer 2009-9-28 San Francisco/U.S.A.
Nakayama‚ T.‚ Motohashi‚ S.‚ and Okamoto‚ Y. iNKT cell based immunotherapy for cancer.
Japanese-German Cancer Workshop 2009-9-16 Hamburg/Germany
Motohashi S‚ Nagato K‚ Taniguchi M‚ Nakayama T‚ Yoshino I. ¦Á-Galactosylceramide-pulsed antigen presenting cell treatment in patients with advanced NSCLC
13th World Conference on Lung Cancer 2009-7-31 San Francisco/U.S.A.
Nagato‚ K.‚ Motohashi‚ S.‚ Yoshino‚ I.‚ Taniguchi‚ M.‚ and Nakayama‚ T. Accumulation of activated V¦Á24 invariant natural killer T cells in the tumor microenvironment after ¦Á-Galactosylceramide-pulsed antigen presenting cell treatment.
The 5th International Symposium on CD1/NKT cells 2009-3-23 Kamakura/Japan
Motohashi S‚ Nagato K‚ Yoshino I‚ Taniguchi M‚ Nakayama T. A Phase I-II study of ¦ÁGalCer-pulsed antigen presenting cells in patients with advanced or recurrent non-small cell lung cancer.
The 5th International Symposium on CD1/NKT Cells 2009-3-23 Kamakura/Japan
Kunii N‚ Motohashi S‚ Yamamoto H‚ Okita K‚ Nagato K‚ Horiguchi S‚ Taniguchi M‚ Okamoto Y‚ Nakayama T. Combination therapy of activated NKT cells and ¦ÁGalCer-pulsed antigen presenting cells in patients with recurrent head and neck cancer.
The 5th International Symposium on CD1/NKT Cells 2009-3-23 Kamakura/Japan
Okamoto Y‚ Kunii N‚ Horiguchi S‚ Uchida T‚ Sakurai D‚ Motohashi S‚ Taniguchi M‚ Nakayama‚ T. Immunotherapy of nasal submucosal injection of ¦Á-Galactosylceramide-pulsed antigen presenting cells or with combination of intra-arterial infusion of activated natural killer T cells in patients with head and neck squamous cell cancer.¡¡
The 1st Chiba University G-COE Symposium‚ 2009-1-6 Tokyo/Japan
Motohashi S Accumulation of activated V¦Á24 invariant natural killer T cells in the tumor microenvironment after ¦Á-Galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cell treatment
The 1st Chiba University G-COE Symposium 2009-1-6 Tkyo/Japan
